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Abstract: Atopic dermatitis is a chronic, inﬂ  ammatory skin condition that affects 10% to 
20% of children and 1% to 3% of adults in the US. Symptoms often result in sleeplessness, 
psychological stress, poor self-esteem, anxiety, and poor school or work performance. The cost 
of atopic dermatitis is estimated to be US$0.9 to 3.8 billion every year. Topical steroids are 
ﬁ  rst-line treatment for atopic dermatitis, and recent advances in vehicle technologies have 
resulted in improved patient tolerability and compliance. Topical calcineurin inhibitors are also 
safe and effective topical treatments for atopic dermatitis, and provide an additional therapeutic 
option for patients with this disease. Systemic immunomodulators are used in the treatment of 
severe refractory disease. Cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and 
interferon gamma have been used in the management of severe atopic dermatitis. This review 
highlights the current and emerging trends in the treatment of atopic dermatitis.
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Introduction
Atopic dermatitis is a chronic, inﬂ  ammatory skin condition that affects 10% to 
20% of children and 1% to 3% of adults in the US (Lipozencic and Wolf 2007). 
Symptoms include erythema, scaling and pruritus in affected areas, and often result 
in sleeplessness, psychological stress, poor self-esteem, anxiety, and poor school 
or work preformance. The cost of atopic dermatitis is estimated to be US$0.9 to 
3.8 billion every year, with direct medical costs and out-of-pocket expenses averaging 
US$609/patient/year (Munzenberger and Montejo 2007). Topical steroids have been 
the mainstay of treatment for atopic dermatitis in both children and adults for over 
50 years. Recent advances in vehicle technologies have resulted in the development 
of novel gel and foam formations of several topical steroids, and have improved 
patient tolerability and compliance. Although the efﬁ  cacy of topical steroids is well-
established, use may be limited by potential side effects and many patients with more 
severe disease require additional therapy. Topical calcineurin inhibitors have proven 
to be safe and effective in the treatment of atopic dermatitis, providing an additional 
therapeutic option for patients with this disease. In addition to advances in topical 
treatments for atopic dermatitis, systemic immunomodulators are becoming more 
prevalent in the treatment of severe, refractory disease. Cyclosporine, methotrexate, 
azathioprine, mycophenolate mofetil, and interferon gamma (IFN-γ) have been used 
in the management of severe atopic dermatitis. The aim of this review is to present 
the current and emerging trends in the treatment of atopic dermatitis.
Topical steroids: new formulations
The use of topical corticosteroids in dermatology began only 50 years ago, yet these 
medications are now considered ﬁ  rst-line therapy for adult and pediatric patients Patient Preference and Adherence 2008:2 388
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with atopic dermatitis (Stahn et al 2007). Topical steroids 
have immunosuppressive, anti-inﬂ  ammatory, antiprolifera-
tive, and vasoconstrictive effects that have been shown to 
reduce itching, improve the appearance of skin, and improve 
quality of life. Until recently, only creams, ointments, and 
lotions were available, but now new hydrogel and foam 
formulations have been developed. These advances in 
vehicle technology provide additional therapeutic options 
for patients with atopic dermatitis, and may enhance patient 
compliance and acceptability. Side effects associated 
with topical steroid use include cutaneous atrophy, striae, 
telangiectasias, contact dermatitis, Cushing’s syndrome, 
growth retardation, and suppression of the hypothalmamic-
pituitary-adrenal axis (Eichenﬁ  eld et al 2007; Wolverton 
2007). These potential side effects can be concerning to 
both patients and physicians and may result in decreased 
prescribing and compliance.
Topical calcineurin inhibitors
Topical tacrolimus and pimecrolimus are calcineurin 
inhibitors that were developed for the treatment of atopic 
dermatitis. Inhibition of calcineurin results in decreased 
transcription of IL-2, with resulting decreases in T-cell 
activation and cytokine production. Topical calcineurin 
inhibitors (TCIs) cause depletion of inﬂ  ammatory dendritic 
cells in atopic dermatitis lesions, decrease histamine release 
from mast cells and basophils, and prevent the T-cell 
proliferation that results from Staphylococcus aureus super-
antigens (Wolverton 2007). One of the greatest advantages 
of these newer medications is the absence of many of the 
side effects associated with topical corticosteroids, including 
cutaneous atrophy, striae, telangiectasias, and hypothalamic-
pituitary-adrenal (HPA) axis suppression. TCIs have been 
shown to be safe and effective in numerous clinical trials, 
and provide additional therapeutic options for the treatment 
of atopic dermatitis.
Currently, Food and Drug Administration (FDA) 
guidelines for the use of TCIs recommend that these 
medications should not be used in children younger than 
2 years of age or in immunocompromised patients. TCIs 
are indicated as short-term or non-continuous, long-term 
treatment of atopic dermatitis in patients who have not 
responded to other topical treatments, or in whom these other 
treatments are not recommended. Pimecrolimus 1% cream is 
FDA-approved for the treatment of mild to moderate atopic 
dermatitis in patients 2 years of age or older. Tacrolimus 
0.1% ointment is approved for the treatment of moderate to 
severe atopic dermatitis in patients 16 years of age or older, 
and tacrolimus 0.03% ointment is approved for use in patients 
2 years of age or older (Paller et al 2005; Munzenberger and 
Montejo 2007; Wolverton 2007).
A comparative study of tacrolimus 0.1% ointment 
demonstrated efﬁ  cacy comparable to the midpotency cortico-
steroid hydrocortisone butyrate 0.1% (Reitamo et al 2002a). 
A study of pediatric patients showed superior efﬁ  cacy of 
0.03% and 0.1% tacrolimus ointment when compared to 
hydrocortisone acetate 1% (Reitamo et al 2002b).
Multiple clinical trials evaluating pimecrolimus 
cream 1% for the treatment of atopic dermatitis demonstrated 
superior efﬁ  cacy when compared with vehicle creams, as well 
as reduced frequency of ﬂ  ares, and reduced need for topical 
corticosteroids (Lebwohl and Gower 2006).
Finally, 3 multi-center, randomized, investigator-blinded 
studies involving a total of 1065 adult and pediatric patients 
with mild to very severe atopic dermatitis compared the 
efficacy and safety of tacrolimus ointment to pimecro-
limus cream. Tacrolimus ointment was found to be 
signiﬁ  cantly more effective than pimecrolimus cream in 
adults and children with moderate to very severe disease. 
In pediatric patients with mild disease, the improvements in 
the tacrolimus group were signiﬁ  cantly greater at week one 
and trended towards continued advantage at the end of the 
study. Patients treated with tacrolimus also showed faster 
onset of action, and greater improvement in itch scores, 
percentage of body surface area affected and Investigator 
Global AD Assessment scores. There was no signiﬁ  cant dif-
ference in adverse events between the two treatment groups. 
The number of local application site reactions experienced on 
day one was greater in adults treated with tacrolimus, but the 
incidence on all subsequent days was equal in both groups. 
More patients in the pimecrolimus group withdrew from the 
studies due to lack of efﬁ  cacy (Paller et al 2005).
The most common adverse effects associated with the use 
of TCIs are local application site reactions. These include skin 
burning, stinging and pruritus. Unlike topical corticosteroids, 
TCIs have not been found to cause HPA axis suppression, 
skin atrophy, striae, or telangiectasias, and are safe to use 
even on the thin skin of the face and neck.
A black box warning and patient medication guide 
were added to TCI labels in January 2006 due to safety 
concerns raised by the FDA (Lebwohl and Gower 2006). 
These concerns were related to the immunosuppression and 
increased incidence of lymphoproliferative disease associ-
ated with systemically-administered calcineurin inhibitors in 
transplant patients, and to studies in animal models involving 
high doses of orally-administered drug. Although rare cases Patient Preference and Adherence 2008:2 389
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of lymphoma and skin malignancies have been reported in 
post-marketing surveillance studies, no causal relationship 
has been established between these cases and the use of 
TCIs, and the reported lymphoma cases were no greater than 
the expected rate in the general population (Lebwohl and 
Gower 2006; Munzenberger and Montejo 2007). Numerous 
pharmacokinetic studies have shown that the administration 
of topical pimecrolimus or tacrolimus results in negligible 
amounts of drug absorption into the systemic circulation 
(Munzenberger and Montejo 2007). After careful review 
of safety data, The American Academy of Dermatology, 
the American College of Allergy, Asthma and Immunol-
ogy and the American Academy of Allergy, Asthma and 
Immunology released statements that data did not suggest 
increased malignancy risk with the use of TCIs and that they 
did not support the black-box warning (Lebwohl and Gower 
2006; Munzenberger and Montejo 2007).
Cyclosporine
Cyclosporine A (CsA) was isolated from the soil fungus 
Tolypocladium inﬂ  atum in 1970. This medication is a potent 
immunosuppressant that inhibits cell-mediated immunity, 
and was approved in the US in 1983 for the prophylaxis of 
organ transplant rejection (Lee et al 2004; Wolverton 2007). 
Cyclosporine is now approved in the US for the treatment 
of psoriasis, and is licensed in Europe for the short-term 
treatment of severe atopic dermatitis in adults (Harper et al 
2000). In the US, cyclosporine is used off-label for the short-
term treatment of severe atopic dermatitis in both children 
and adults. Cylosponine shares a common mechanism of 
action with the TCIs. This medication inhibits calcineurnin, 
resulting in decreased production of IL-2 and other inﬂ  amma-
tory cytokines and preventing the activation and proliferation 
of T cells. Due to its high molecular weight, cyclosporine is 
not effective topically and must be administered orally.
A large meta-analysis of 15 European studies evaluated 
the use of cyclosporine in the treatment of severe atopic 
dermatitis in over 600 children and adults. Treatment duration 
ranged from 6 weeks to 12 months. All studies showed a 
mean decrease in the severity of atopic dermatitis. Twelve of 
the studies were pooled, and the results demonstrated dose-
related improvements in atopic dermatitis with cyclosporine 
treatment. Two weeks into treatment, patients receiving 
low-dose therapy (3 mg/kg) showed a mean decrease in 
disease severity of 22%, and patients on high dose therapy 
(4 mg/kg) showed a 40% decrease in disease severity. After 
6 to 8 weeks, relative effectiveness was 55%. Three of the 
included studies assessed health-related quality of life and 
all three found signiﬁ  cant improvements with cyclosporine 
treatment. Adverse events included reversible increases 
in creatinine, hypertension, infections, gastrointestinal 
symptoms, headache and paresthesias (Schmitt et al 2007).
A retrospective review of 15 Chinese patients ages 1 to 
58 years with severe atopic dermatitis treated with oral cyclo-
sporine demonstrated rapid improvement in disease severity 
2 weeks after initiating treatment. At the end of treatment, 
73% of the patients showed improvement in their disease; 
however, relapses were noted in all patients within 3 months 
of cessation of cyclosporine. Worsening blood pressure 
occurred in 1 patient who had borderline hypertension prior 
to cyclosporine treatment; return to baseline occurred after 
cessation of cyclosporine (Lee et al 2004).
A retrospective study of 73 adult patients from the 
Netherlands evaluated the long-term safety and efﬁ  cacy 
of cyclosporine A for the treatment of atopic dermatitis. 
Patients received treatment for an average of 1.3 years, with 
doses ranging from 2.5 to 5 mg/kg/day. Successful treatment 
(50%–100% improvement) was achieved in 77%, moderate 
(50%) improvement in 16%, and no improvement in 7% of 
patients. The authors note that most patients demonstrated 
rapid improvement within the ﬁ  rst few weeks of treatment. 
Serum creatinine levels rose 30% from baseline in 9.6% of 
patients, and hypertension developed in 15.1% of patients. 
Other side effects reported included paresthesias, hypertri-
chosis, headaches, fatigue, nausea, gingival hyperplasia, 
muscle cramps, folliculitis, and tremors. Upon discon-
tinuation of cyclosporine, 45% of the patients experienced 
remission of their atopic dermatitis for at least 3 months, 
and 55% experienced relapse. Of note, 8% of patients who 
relapsed developed rebound disease that was more severe 
than baseline (Hijnen et al 2007).
A prospective, randomized trial of 40 British children 
with atopic dermatitis compared the efficacy, safety, 
tolerability and quality of life of short-course and continuous 
treatment with cyclosporine. Children ages 2 to 16 years 
with severe atopic dermatitis were treated with either 
multiple short courses of 12 weeks each of cyclosporine 
5 mg/kg or with continuous therapy for one year. Improve-
ments in severity, area of involvement, irritability and sleep 
disturbance were statistically signiﬁ  cant in both groups 
from baseline to weeks 8, 12, and month 12. Although no 
signiﬁ  cant differences were seen between the groups at any 
particular time point, improvements ﬂ  uctuated in the short 
course arm as a result of medication tapering and cessation. 
No patients showed clinically signiﬁ  cant changes in serum 
creatinine or blood pressure, and tolerability was considered Patient Preference and Adherence 2008:2 390
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good or very good in at least 80% of the patients. Although 
the mean cumulative dose of cyclosporine was greater in 
continuous arm than in the short-course arm (1068 and 
836 mg/kg, respectively), the patients in the continuous 
arm demonstrated more consistent disease control (Harper 
et al 2000).
Methotrexate
Methotrexate is a folic acid antagonist that is approved for 
the treatment of psoriasis, rheumatoid arthritis, and mycosis 
fungoides (Wolverton 2007). Randomized controlled trials are 
lacking, but several small trials reported clinical improvement 
of moderate to severe atopic dermatitis in patients treated with 
methotraxate. A prospective trial of 12 patients evaluated the 
use of methotrexate for the treatment of moderate to severe 
atopic dermatitis. The average improvement in disease activity 
was 50% from baseline, and there were signiﬁ  cant improve-
ments in quality of life, affected body surface area, and loss 
of sleep and itch scores (Weatherhead et al 2007). Although 
the use of methotrexate in atopic dermatitis is off label, its 
anti-inﬂ  ammatory effects make it a useful second-line agent 
for the treatment of atopic dermatitis. Side effects include 
nausea and elevated liver enzymes, and patients occasion-
ally develop pancytopenia or hepatic or pulmonary toxicity 
(Goujon et al 2006; Weatherhead et al 2007; Wolverton 
2007). Patients should be monitored closely when therapy 
is intiated, with complete blood count, liver enzymes, and 
creatinine levels 1 to 2 weeks after initiation of therapy and 
after any changes in dosing. Once long-term dosing levels 
have been established, repeat testing should be obtained every 
3 to 4 months (Wolverton 2007).
Azathioprine
Azathioprine was initially developed for the prevention 
of graft rejection in organ transplant patients. Addition-
ally, azathiaprine’s immunosuppressive properties make 
it a useful treatment for a number of diseases, including 
systemic lupus erythematosis, dermatomyositis, pemphigus 
vulgaris, and atopic dermatitis (Meggitt and Reynolds 2001). 
Azathioprine is converted into 6-mercaptopurine, a purine 
analog that produces metabolites that incorporate into DNA. 
Although data on the use of azathioprine for atopic dermatitis 
are limited, there are several studies that support its use as a 
second-line treatment for severe, refractory disease. A review 
of 8 studies involving a total of 128 adult and pediatric patients 
treated with azathioprine documented overall improvement 
in atopic dermatitis symptoms in 7 of the 8 studies (Meggitt 
and Reynolds 2001). In addition, a double-blind, randomized, 
placebo-controlled crossover study evaluated the safety and 
efﬁ  cacy of azathioprine 2.5 mg/kg/day for 12 weeks in adult 
patients with severe atopic dermatitis. Subjects were evaluated 
using the SASSAD (Six Area Six Sign Atopic Dermatitis) sign 
score and demonstrated 26% reduction during azathioprine 
treatment, but only a 3% reduction with placebo. Pruritus, sleep 
disturbance, and disruption of work/daytime activity showed 
signiﬁ  cant improvements during azathioprine treatment but 
not with placebo treatment. While receiving azathioprine 
treatment, 14 subjects reported gastrointestinal side effects, 
8 demonstrated abnormalities in their liver enzymes, and 
2 became leukopenic (Berth-Jones et al 2002).
The most common serious side effects of azathioprine are 
dose-dependant hepatotoxicity and myelotoxicity. Myelotox-
icity has been shown to be related to activity of thiopurine 
methyltransferase (TPMT), an enzyme necessary for the 
metabolism of azathioprine. Approximately 10% of the 
population are heterozygous at the TPMT locus and demon-
strate intermediate TPMT activity, putting them at increased 
risk for myelosupression when treated with azathoprine. 
Homozygous deﬁ  ciency of TPMT is found in 0.33% of the 
population, and these individuals are likely to show profound 
myelosuppression when treated with azathioprine (Meggitt 
and Reynolds 2001). A double-blind, placebo-controlled 
trial evaluated the safety and efﬁ  cacy of azathioprine dosed 
by TPMT activity in moderate to severe atopic dermatitis. 
Patients with normal TPMT activity received 2.5 mg/kg/day, 
while those with heterozygous range TPMT activity received 
1 mg/kg.day. At week 12, there was a 37% improvement in 
mean disease activity in the azathioprine group compared 
with 20% in the placebo group. Although response to the drug 
varied widely among participants, subjects with heterozygous 
TPMT activity responded to the medication in similar propor-
tions to the participants with normal TPMT activity, and did 
not develop myelotoxicity (Meggitt et al 2006).
Concerns also exist that long-term use of this medication 
may increase the risk of certain malignancies. These concerns 
stem from the increased rate of squamous cell skin cancers 
and non-Hodgkin’s lymphoma in organ transplant patients 
who have received long-term immunosuppressive therapy 
that included azathioprine. However, studies of patients 
taking short- or medium-term courses of azathioprine do not 
demonstrate this increased risk of carcinogenicity (Meggitt 
and Reynolds 2001).
Mycophenolate mofetil
Mycophenolate mofetil (MMF) has been used recently in 
the treatment of adult and pediatric patients with moderate Patient Preference and Adherence 2008:2 391
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to severe refractory atopic dermatitis. Although randomized 
controlled trials have not yet been done, several studies have 
demonstrated symptom improvement in patients treated with 
this drug (Heller et al 2007; Murray and Cohen 2007).
MMF is a selective reversible inhibitor of inosine 
monophosphate dehydrogenase, an enzyme necessary for 
the de novo synthesis of purines. Lymphocytes lack the 
salvage pathway present in other inﬂ  ammatory cell types, and 
are therefore dependent on the de novo synthesis pathway. 
Inosine monophosphate dehydrogenase inhibition results in 
selective suppression of lymphocytes.
A retrospective chart review examined 20 adult patients 
with moderate to severe atopic dermatitis treated with 
mycophenolate mofetil at starting doses of 500 mg to 1 g twice 
daily. Seventeen of the 20 patients showed improvement in 
disease severity after 2 to 4 weeks and were maintained on 
treatment. Ten patients eventually achieved complete clearance 
of atopic dermatitis and were tapered off of MMF. Although 
MMF was generally well tolerated, side effects included 
mild headaches, gastrointestinal complaints and fatigue. Four 
patients developed herpes zoster, 1 developed herpes simplex, 
and 2 developed cutaneous infections with Staphylococcus 
aureus (Murray and Cohen 2007).
A retrospective study of 14 pediatric patients with severe 
atopic dermatitis demonstrated that MMF was both a safe and 
effective treatment option. Over half of the patients achieved 
complete or almost complete clearance, and only one failed to 
respond. The authors initiated dosing at 40 to 50 mg/kg daily 
in younger children and 30 to 40 mg/kg daily in adolescents. 
They noted that initial responses typically occurred within 
2 months, with maximal effect attained after 2 to 3 months. 
They reported no infectious complications in their cohort 
(Heller et al 2007).
IFN-γ
Interferon gamma (IFN-γ) is a cytokine that exerts 
anti-inﬂ  ammatory effects by inhibiting IgE synthesis and 
T cell proliferation (Meagher et al 2002). Treatment with 
IFN-γ has been shown to decrease blood eosinophil counts 
in patients with atopic dermatitis, and has been shown to 
improve atopic dermatitis symptoms in patients with severe 
disease (Jang et al 2000). A controlled trial of 51 patients 
with severe, recalcitrant atopic dermatitis compared low-dose 
(0.5 × 106 IU/m2) IFN-γ, high-dose (1.5 × 106 IU/m2) IFN-γ, 
and placebo treatment 3 times per week over 12 weeks. Both 
groups treated with IFN-γ showed signiﬁ  cant reduction in 
disease severity. The high-dose group showed more rapid and 
effective treatment outcome at week 6, but improvement in 
both groups remained stable after week 8, leading the authors 
to suggest a regimen of initial high-dose therapy, followed 
by maintenance therapy at the lower dosage. Potential side 
effects associated with IFN-γ therapy include transient fever, 
myalgias, respiratory difﬁ  culties, and elevation of LDH or 
transaminases (Jang et al 2000).
Conclusion
Atopic dermatitis is a chronic inﬂ  ammatory skin disease that 
affects both children and adults and causes signiﬁ  cant physical, 
psychological, social, and emotional stress for patients and their 
families. Although topical steroids have been the ﬁ  rst-line treat-
ment for atopic dermatitis for the past half century, advances in 
our understanding of disease pathogenesis and new develop-
ments in immunosuppressive medications have expanded the 
therapeutic options available to treat this disease. The topical 
medications available for atopic dermatitis have expanded to 
incorporate new vehicle technologies as well as steroid-sparing 
topical calcineurin inhibitors. The use of systemic immunosup-
pressants, including cyclosporine, methotrexate, azathioprine, 
mycophenilate mofetil, and IFN-γ has become more common, 
particularly for severe, refractory disease.
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